Hadasit Bio-Holdings

About Hadasit

Hadasit Medical Research Services & Development Ltd. was established as a subsidiary of Hadassah Medical Organization (HMO) in Jerusalem, Israel for the purpose of promoting and commercializing its continuously generated intellectual property (IP) and R&D capabilities, aimed at finding solutions to problems faced by modern medicine. IP generated by HMO has already gained a place of honor in the international medical research arena with cutting-edge biomedical technology for the development of novel therapeutics, diagnostic methods and devices.

's ultimate responsibility is to guide technologies from innovation to commercial application. In order to accomplish this transformation, Hadasit is equipped with the full-spectrum of resources and capabilities required for composing and conducting the "symphony" of pre-clinical services & clinical studies, establishing start-up companies, offering product licensing and providing international consulting services.

, together with strategic partners, has established a number of start-up companies based on technologies fully or partially developed at Hadassah Medical Organization. HMO identifies platform technologies as IP in a specific area and Hadasit is assigned to commercialize that IP either via granting a product license to Biotech or Pharma companies or via the creation of a daughter company which operates in the premise of HMO.

Hadasit Bio-Holdings Ltd. (TASE: HDST) is a unique opportunity in the landscape of technology transfer offices & companies world-wide. It offers a fertile environment for the wedding of science, medicine, academia and business – within the framework of which a cluster of companies, focusing on a variety of therapeutic areas, will enjoy the benefits of a public offering. This framework serves to address an inherent problematic characteristic of investment in early-stage biotech by distributing both risk and the chance of success amongst a number of companies.


Part of Hadasit's start-up companies are situated in the BioPark at Hadassah's Ein Kerem campus in Jerusalem. A joint project of HMO and the Hebrew University (HU) of Jerusalem, the HMO/HU BioPark is the first medical research-oriented industrial park in Israel and enjoys close vicinity to Hadassah University Hospital's rich infrastructure of state-of-the-art GMP-compliant facilities and FDA-certified clinical trial capabilities.